DK0778023T3 - Produkt indeholdende rapamycin eller udvalgte derivater deraf og en NMDA- eller AMPA-antagonist til anvendelse ved behandling af epilepsi eller Huntingtons sygdom, og anvendelse af rapamycin eller udvalgte derivater deraf..... - Google Patents

Produkt indeholdende rapamycin eller udvalgte derivater deraf og en NMDA- eller AMPA-antagonist til anvendelse ved behandling af epilepsi eller Huntingtons sygdom, og anvendelse af rapamycin eller udvalgte derivater deraf.....

Info

Publication number
DK0778023T3
DK0778023T3 DK96308786T DK96308786T DK0778023T3 DK 0778023 T3 DK0778023 T3 DK 0778023T3 DK 96308786 T DK96308786 T DK 96308786T DK 96308786 T DK96308786 T DK 96308786T DK 0778023 T3 DK0778023 T3 DK 0778023T3
Authority
DK
Denmark
Prior art keywords
rapamycin
selected derivatives
nmda
huntington
epilepsy
Prior art date
Application number
DK96308786T
Other languages
Danish (da)
English (en)
Inventor
Katherine Lu Molnar-Kimber
Stephen Shi-Hsun Lin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK0778023T3 publication Critical patent/DK0778023T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96308786T 1995-12-07 1996-12-04 Produkt indeholdende rapamycin eller udvalgte derivater deraf og en NMDA- eller AMPA-antagonist til anvendelse ved behandling af epilepsi eller Huntingtons sygdom, og anvendelse af rapamycin eller udvalgte derivater deraf..... DK0778023T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
DK0778023T3 true DK0778023T3 (da) 2003-06-30

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96308786T DK0778023T3 (da) 1995-12-07 1996-12-04 Produkt indeholdende rapamycin eller udvalgte derivater deraf og en NMDA- eller AMPA-antagonist til anvendelse ved behandling af epilepsi eller Huntingtons sygdom, og anvendelse af rapamycin eller udvalgte derivater deraf.....

Country Status (23)

Country Link
EP (1) EP0778023B1 (hu)
JP (1) JPH09183727A (hu)
KR (1) KR970032856A (hu)
CN (1) CN1112925C (hu)
AR (1) AR008747A1 (hu)
AT (1) ATE234095T1 (hu)
AU (1) AU700653B2 (hu)
BR (1) BR9605895A (hu)
CA (1) CA2192298A1 (hu)
CZ (2) CZ6498A3 (hu)
DE (1) DE69626610T2 (hu)
DK (1) DK0778023T3 (hu)
ES (1) ES2188730T3 (hu)
HU (1) HUP9603370A3 (hu)
IL (1) IL119778A (hu)
MX (1) MX9606131A (hu)
NO (1) NO309966B1 (hu)
NZ (1) NZ299888A (hu)
PT (1) PT778023E (hu)
SI (1) SI0778023T1 (hu)
SK (1) SK154796A3 (hu)
TW (1) TW427904B (hu)
ZA (1) ZA9610245B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
EP1622625A1 (en) * 2003-04-09 2006-02-08 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof
CN1863810B (zh) 2003-04-09 2010-12-01 惠氏公司 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
WO2006068932A2 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
AU2010233073B2 (en) * 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US20120122913A1 (en) * 2009-07-24 2012-05-17 Institut National De La Recherche Scientifque Combination of curcuminoids and mtor inhibitors for the treatment of tauopathies
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) * 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
LT3003268T (lt) 2013-06-05 2018-12-10 Pharnext Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US20200354445A1 (en) * 2017-11-15 2020-11-12 Vanderbilt University Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
MX9606131A (es) 1997-08-30
AU700653B2 (en) 1999-01-14
SI0778023T1 (en) 2003-08-31
CZ6498A3 (cs) 1998-06-17
SK154796A3 (en) 1997-09-10
DE69626610T2 (de) 2003-10-02
AU7417896A (en) 1997-06-12
DE69626610D1 (de) 2003-04-17
IL119778A (en) 1999-07-14
EP0778023A1 (en) 1997-06-11
IL119778A0 (en) 1997-03-18
HU9603370D0 (en) 1997-01-28
ZA9610245B (en) 1998-06-05
CA2192298A1 (en) 1997-06-08
NO965238L (no) 1997-06-09
NZ299888A (en) 2001-02-23
CZ354496A3 (cs) 1998-03-18
EP0778023B1 (en) 2003-03-12
NO309966B1 (no) 2001-04-30
PT778023E (pt) 2003-06-30
ES2188730T3 (es) 2003-07-01
HUP9603370A2 (en) 1997-05-28
HUP9603370A3 (en) 1998-12-28
ATE234095T1 (de) 2003-03-15
KR970032856A (ko) 1997-07-22
AR008747A1 (es) 2000-02-23
CN1112925C (zh) 2003-07-02
CN1159915A (zh) 1997-09-24
TW427904B (en) 2001-04-01
JPH09183727A (ja) 1997-07-15
NO965238D0 (no) 1996-12-06
BR9605895A (pt) 1998-08-18

Similar Documents

Publication Publication Date Title
DK0778023T3 (da) Produkt indeholdende rapamycin eller udvalgte derivater deraf og en NMDA- eller AMPA-antagonist til anvendelse ved behandling af epilepsi eller Huntingtons sygdom, og anvendelse af rapamycin eller udvalgte derivater deraf.....
DE69626961D1 (de) Wegwerfkleidungsstück, verfahren und vorrichtung zu dessen herstellung
HUP9800725A3 (en) 4-benzoyl-pyrozol derivatives, process for their preparation and their use as herbicides
DE69635023D1 (de) Ulmwh (ultra-low-molecular weight heparin) zur behandlung von asthma
DE69629865D1 (de) Intraluminale medische Vorrichtung, insbesondere Blutfilter
NL1000352C2 (nl) Elektronisch betaalsysteem met verschillende rekeneenheden, elektronisch betaalmiddel alsmede werkwijze voor elektronisch betalen.
AU7419996A (en) Device for removing toxic substances from the blood
DE69633631D1 (de) Target, verfahren zu dessen herstellung und herstellung hochrefraktiver filme
NO902319D0 (no) Fremgangsmaate for aa bestemme egenskaper vedroerende stroemingsdynamikk for flerfasestroemning.
FR2704458B1 (fr) Ensemble de distribution de produit.
NO981800D0 (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
PT853617E (pt) Novos derivados de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo
DE69629671D1 (de) Netzbares produkt
NO962434L (no) Titanlegering, titanlegeringsgjenstand og fremgangsmåte for fremstilling av denne
NL1009113A1 (nl) Polyaryleenaminen en werkwijze voor de bereiding ervan.
FR2762217B1 (fr) Preparation solide vitamino-calcique, son procede d'obtention et son utilisation
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
NL1003127A1 (nl) Werkwijze voor het bereiden van 5-amino-2,4,6-trijodoisoftaalzuur- dichloride.
ATE174766T1 (de) Lebensmittel und verfahren zu dessen herstellung
PT851865E (pt) Derivados de 12h-dibenzo¬d,g|¬1,3|dioxina
DE69625174D1 (de) Gleitteil und verfahren zu dessen herstellung
DE10085042T1 (de) Drahtförmiges Produkt, Verfahren zu seiner Herstellung, und aus dem Produkt hergestelltes Verschleissteil
DE69300253D1 (de) Sulfonamidderivate, Verfahren zu ihrer Herstellung und diese enthaltende Herbizide.
BA96113A (bs) Derivati 12,11113-epoksi-tilozina i postupci za njihovo dobivanje
NO983492D0 (no) 2,3-disubstituerte cyklopentanderivater, fremgangsmÕte for fremstilling derav, og medisinsk anvendelse derav